Urothelial cancer
1 – 10 of 136
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma—commentary on patient-reported outcomes in EV-302
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re : Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.11.014
(2026) In European Urology Focus
- Contribution to journal › Letter
-
Mark
Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer
- Contribution to journal › Article
-
Mark
CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer
- Contribution to journal › Article
-
Mark
Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System
- Contribution to journal › Article
-
Mark
Healthcare Resource Utilisation in Patients with Upper Tract Urothelial Carcinoma : Healthcare
- Contribution to journal › Article
- 2025
-
Mark
Pre-treatment metastatic biopsy : a step towards precision oncology for urothelial cancer
- Contribution to journal › Scientific review
-
Mark
The association between animal protein, plant protein, and their substitution with bladder cancer risk : a pooled analysis of 10 cohort studies
- Contribution to journal › Article
-
Mark
Reply to Laila Schneidewind, Fabian P. Stangl, Jennifer Kranz, and Gernot Bonkat's Letter to Editor re : Fredrik Liedberg, Evanguelos Xylinas, Paolo Gontero. Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guérin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box? Eur Urol Focus 2024;10:564–6
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting
- Contribution to journal › Article
